跳至主要内容
临床试验/jRCT1030230668
jRCT1030230668招募中不适用

Clinical performance study of AIA-CL PS-PLA1 (Phosphatidylserine-specific Phos pholipase A1) assay reagent for systemic lupus erythematosus (SLE)

TOSOH Corporation0 个研究点目标入组 300 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
300
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
No limit 至 No limit(—)

入选标准

  • SLE patients (untreated, treated intervention), non-SLE connective tissue disease patients (rheumatoid arthritis, other antinuclear antibody-related connective tissue diseases [Sjogren's syndrome, systemic sclerosis, polymyositis/dermatomyositis, mixed connective tissue disease], antiphospholipid antibody syndrome), non-connective tissue disease subjects

排除标准

  • Patients with thyroid disorders (Graves' disease, thyroiditis, Plummer's disease, Hashimoto's disease)
  • Pregnant women
  • Non-connective tissue disease subjects who are antinuclear antibody positive

结局指标

主要结局

-

Discriminatory evaluation of SLE using PS-PLA1

次要结局

  • Sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve (AUC) by ROC analysis
  • Transition of PS-PLA1, anti-ds-DNA antibodies, and SLEDAI values

研究者

相似试验